Cover Image
市場調查報告書

Orexo AB - 產品平台檢討

Orexo AB - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 200986
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Orexo AB - 產品平台檢討 Orexo AB - Product Pipeline Review - 2014
出版日期: 2014年03月31日 內容資訊: 英文 29 Pages
簡介

Orexo AB (Orexo) 致力於新興、熱門的醫藥品之研究開發及製藥、登記、商品化。此外也廣泛活用自家產業規模及技術以助於新藥的開發。

本報告提供Orexo AB的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Orexo AB的基本資料

Orexo AB概要

  • 主要資訊
  • 企業資料

Orexo AB:R&D概要

  • 主要的治療範圍

Orexo AB:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Orexo AB:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Orexo AB:藥物簡介

  • alfentanil hydrochloride
  • OX-AAF
  • OX-CLI

Orexo AB:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Orexo AB:最近的開發平台趨勢

Orexo AB:暫停中的計劃

Orexo AB:中止開發的開發中產品

  • 中止開發的開發中產品簡介
  • (omeprazole + famotidine)
  • OX-914
  • OX-CLI
  • OX-ESI

Orexo AB:企業發表

Orexo AB:總公司和子公司的所地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04749CDB

Global Markets Direct's, 'Orexo AB - Product Pipeline Review - 2014', provides an overview of the Orexo AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Orexo AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Orexo AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Orexo AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Orexo AB's pipeline products

Reasons to buy

  • Evaluate Orexo AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Orexo AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Orexo AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Orexo AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Orexo AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Orexo AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Orexo AB Snapshot
    • Orexo AB Overview
    • Key Information
    • Key Facts
  • Orexo AB - Research and Development Overview
    • Key Therapeutic Areas
  • Orexo AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Orexo AB - Pipeline Products Glance
    • Orexo AB - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Orexo AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Orexo AB - Drug Profiles
    • alfentanil hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OX-AAF
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OX-CLI
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Orexo AB - Pipeline Analysis
    • Orexo AB - Pipeline Products by Target
    • Orexo AB - Pipeline Products by Route of Administration
    • Orexo AB - Pipeline Products by Molecule Type
    • Orexo AB - Pipeline Products by Mechanism of Action
  • Orexo AB - Recent Pipeline Updates
  • Orexo AB - Dormant Projects
  • Orexo AB - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • (omeprazole + famotidine)
      • OX-914
      • OX-CLI
      • OX-ESI
  • Orexo AB - Company Statement
  • Orexo AB - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Orexo AB, Key Information
  • Orexo AB, Key Facts
  • Orexo AB - Pipeline by Indication, 2014
  • Orexo AB - Pipeline by Stage of Development, 2014
  • Orexo AB - Monotherapy Products in Pipeline, 2014
  • Orexo AB - Out-Licensed Products in Pipeline, 2014
  • Orexo AB - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • Orexo AB - Phase II, 2014
  • Orexo AB - Preclinical, 2014
  • Orexo AB - Pipeline by Target, 2014
  • Orexo AB - Pipeline by Route of Administration, 2014
  • Orexo AB - Pipeline by Molecule Type, 2014
  • Orexo AB - Pipeline Products by Mechanism of Action, 2014
  • Orexo AB - Recent Pipeline Updates, 2014
  • Orexo AB - Dormant Developmental Projects,2014
  • Orexo AB - Discontinued Pipeline Products, 2014
  • Orexo AB, Subsidiaries

List of Figures

  • Orexo AB - Pipeline by Top 10 Indication, 2014
  • Orexo AB - Pipeline by Stage of Development, 2014
  • Orexo AB - Monotherapy Products in Pipeline, 2014
  • Orexo AB - Out-Licensed Products in Pipeline, 2014
  • Orexo AB - Pipeline by Top 10 Target, 2014
  • Orexo AB - Pipeline by Top 10 Route of Administration, 2014
  • Orexo AB - Pipeline by Top 10 Molecule Type, 2014
  • Orexo AB - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top